Plus Therapeutics Inc (NASDAQ:PSTV) president and CEO Dr Marc Hedrick tells Proactive's Stephen Gunnion the company is trying to go after some of the hardest problems in cancer using targeted radio therapeutics.
Hedrick explains that rhenium (186Re) obisbemeda is its lead drug candidate designed for the treatment of recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBCs), such as ependymoma and high-grade glioma.
He also discusses the company's capital-efficient model. Thanks to grants and funding, he says the company has derisked its development program. A cash balance of about $20 million will see it through 2025, he adds.